Expertise in
9
conditions

Prodromos I. Sidiropoulos

Irakleion, ESYE43, GR 
Expertise in
9
conditions
Irakleion, ESYE43, GR 

Overview

Prodromos Sidiropoulos practices practicing medicine in Irakleion, Greece.

Sidiropoulos is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Arthritis, and Rheumatoid Lung Disease.

They are actively involved in clinical research, co-authoring 128 peer reviewed articles and participating in 4 clinical trials.

Locations

Irakleion, ESYE43, Greece
Other Locations
Heraklio, ESYE43, Greece
Thessaloniki, ESYE12, Greece
Rethymno, ESYE43, Greece
Athens, ESYE31, Greece

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis
A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

128 Total Publications

Differential functional and lipidomic impact of tofacitinib and other disease-modifying antirheumatic drugs on HDL in rheumatoid arthritis.
Differential functional and lipidomic impact of tofacitinib and other disease-modifying antirheumatic drugs on HDL in rheumatoid arthritis.
Journal: Scientific reports
Published: April 06, 2026

Frequently Asked Questions about Prodromos I. Sidiropoulos

Is Prodromos I. Sidiropoulos a top-rated expert for Systemic Lupus Erythematosus (SLE)?

MediFind is an objective health platform that identifies experts based on real-world data. Prodromos I. Sidiropoulos is classified as an Distinguished expert for Systemic Lupus Erythematosus (SLE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Prodromos I. Sidiropoulos participate in research or clinical trials?

Yes. Prodromos I. Sidiropoulos has published 128 articles and abstracts on conditions like Systemic Lupus Erythematosus (SLE). You can view a list of Prodromos I. Sidiropoulos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sidiropoulos's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile